Pfizer (NYSE:PFE) was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating in a research note issued to investors on Monday. They presently have a $37.98 price target on the biopharmaceutical company’s stock. Vetr‘s price objective suggests a potential upside of 3.94% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, January 8th. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Friday, January 5th. Nord/LB reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. UBS Group set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Finally, Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $38.83.

Shares of Pfizer (NYSE PFE) opened at $36.54 on Monday. The firm has a market cap of $217,800.00, a PE ratio of 22.42, a P/E/G ratio of 2.44 and a beta of 1.01. Pfizer has a 52 week low of $30.90 and a 52 week high of $37.35. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The business had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.61 earnings per share. equities analysts expect that Pfizer will post 2.59 EPS for the current year.

Pfizer declared that its Board of Directors has initiated a share buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its shares are undervalued.

In other news, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold 29,450 shares of company stock worth $1,065,220 over the last quarter. 0.06% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the company. HL Financial Services LLC lifted its holdings in Pfizer by 1.1% in the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock valued at $108,260,000 after buying an additional 35,744 shares during the period. Hartford Financial Management Inc. lifted its holdings in Pfizer by 10.8% in the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 835 shares during the period. Cadence Bank NA lifted its holdings in Pfizer by 1.4% in the second quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 1,428 shares during the period. Majedie Asset Management Ltd lifted its holdings in Pfizer by 7.9% in the second quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock valued at $11,320,000 after buying an additional 24,531 shares during the period. Finally, Stanley Laman Group Ltd. lifted its holdings in Pfizer by 373.7% in the second quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock valued at $3,839,000 after buying an additional 90,160 shares during the period. Institutional investors own 69.74% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Vetr Downgrades Pfizer (PFE) to Hold” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/01/14/vetr-downgrades-pfizer-pfe-to-hold.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.